# A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

> **NCT06947811** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 71 (estimated)

## Conditions studied

- EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor

## Interventions

- **DRUG:** Almonertinib
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT06947811
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-09
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06947811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06947811, "A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06947811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*